• Je něco špatně v tomto záznamu ?

The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors

G. Korinkova, K. Cwiertka, M. Paprskarova, P. Dzubak, M. Hajduch

. 2010 ; 57 (2) : 161-169.

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12025269

Bohemine and roscovitine are the most important representatives of the group of compounds structurally derived from olomoucine. Biologically they function as inhibitors of cyclin-dependent kinases (CDKs), the key regulators of cell cycle, which is often disrupted in cancer cells resulting in uncontrollable proliferation. Bohemine and roscovitine have demonstrated their cytostatic and cytotoxic in vitro and also in vivo effects. Currently the phase II clinical trials for roscovitine are underway. The aim of the study was to evaluate the potential in vitro radiosensitising effect of bohemine (BOH) and roscovitine (ROS). Clonogenic survival assay and human lung adenocarcinoma cell line A549 were used. Tested schedules were: A-pretreatment, B-concomitant application and C-posttreatment. Concentrations corresponded to IC10, IC25 and IC50 for BOH/ROS (0.1-30 microM). The radiation doses were 1, 2 and 3 Gy. Flow cytometry and western blot analysis were used to characterize cell cycle distribution, BrdU incorporation and DNA repair processes. The highest in vitro radiosensitising effect of BOH/ROS was observed for Schedule A in all tested concentrations (SER(37%) 1.46-3.20). Cell cycle analysis showed an inclination towards G0/G1 delay 48 hours posttreatment and unaltered level of apoptosis. Changes in the DNA repair processes were observed - inhibition of DNA-PK kinase, inhibition of BrdU incorporation, strong and enduring induction of p21 protein and long-lasting phosphorylation of gammaH2AX(Ser139). Certain low concentration activities of BOH/ROS in monotherapy were detected, mainly the activation of DNA-PK kinase. The results demonstrated strong in vitro radiosensitising effect of BOH/ROS that is concentration and especially schedule dependent. The strong cytostatic effect of the pretreatment schedule is mediated through the inhibition/rearrangements of DNA repair processes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12025269
003      
CZ-PrNML
005      
20130129181521.0
007      
ta
008      
120816s2010 xo f 000 0#eng||
009      
AR
024    7_
$a 10.4149/neo_2010_02_161 $2 doi
035    __
$a (PubMed)20099981
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Kořínková, Gabriela $7 xx0087788 $u Laboratory of Experimental Medicine, Department of Pediatrics, Faculty of Medicine, Palacký University & Faculty Hospital in Olomouc, Olomouc, Czech Republic. gabriela.korinkova@seznam.cz
245    14
$a The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors / $c G. Korinkova, K. Cwiertka, M. Paprskarova, P. Dzubak, M. Hajduch
520    9_
$a Bohemine and roscovitine are the most important representatives of the group of compounds structurally derived from olomoucine. Biologically they function as inhibitors of cyclin-dependent kinases (CDKs), the key regulators of cell cycle, which is often disrupted in cancer cells resulting in uncontrollable proliferation. Bohemine and roscovitine have demonstrated their cytostatic and cytotoxic in vitro and also in vivo effects. Currently the phase II clinical trials for roscovitine are underway. The aim of the study was to evaluate the potential in vitro radiosensitising effect of bohemine (BOH) and roscovitine (ROS). Clonogenic survival assay and human lung adenocarcinoma cell line A549 were used. Tested schedules were: A-pretreatment, B-concomitant application and C-posttreatment. Concentrations corresponded to IC10, IC25 and IC50 for BOH/ROS (0.1-30 microM). The radiation doses were 1, 2 and 3 Gy. Flow cytometry and western blot analysis were used to characterize cell cycle distribution, BrdU incorporation and DNA repair processes. The highest in vitro radiosensitising effect of BOH/ROS was observed for Schedule A in all tested concentrations (SER(37%) 1.46-3.20). Cell cycle analysis showed an inclination towards G0/G1 delay 48 hours posttreatment and unaltered level of apoptosis. Changes in the DNA repair processes were observed - inhibition of DNA-PK kinase, inhibition of BrdU incorporation, strong and enduring induction of p21 protein and long-lasting phosphorylation of gammaH2AX(Ser139). Certain low concentration activities of BOH/ROS in monotherapy were detected, mainly the activation of DNA-PK kinase. The results demonstrated strong in vitro radiosensitising effect of BOH/ROS that is concentration and especially schedule dependent. The strong cytostatic effect of the pretreatment schedule is mediated through the inhibition/rearrangements of DNA repair processes.
650    _2
$a adenokarcinom $x farmakoterapie $x patologie $x radioterapie $7 D000230
650    _2
$a apoptóza $x účinky léků $x účinky záření $7 D017209
650    _2
$a western blotting $7 D015153
650    _2
$a buněčný cyklus $x účinky léků $x účinky záření $7 D002453
650    _2
$a cyklin-dependentní kinasy $x antagonisté a inhibitory $x metabolismus $7 D018844
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a lidé $7 D006801
650    _2
$a kinetin $x farmakologie $7 D007701
650    _2
$a nádory plic $x farmakoterapie $x radioterapie $7 D008175
650    _2
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    _2
$a puriny $x farmakologie $7 D011687
650    _2
$a radiosenzibilizující látky $x farmakologie $7 D011838
650    _2
$a nádorové buňky kultivované $x účinky léků $7 D014407
650    _2
$a rentgenové záření $7 D014965
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ćwiertka, Karel, $d 1961- $7 xx0018322
700    1_
$a Paprskářová, Martina $7 xx0086519
700    1_
$a Džubák, Petr $7 xx0080445
700    1_
$a Hajdúch, Marián, $d 1969- $7 xx0050218
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 57, č. 2 (2010), s. 161-169
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20099981 $y Pubmed
910    __
$a ABA008 $b A 1194 $c 659 $y m
990    __
$a 20120816 $b ABA008
991    __
$a 20130129181645 $b ABA008
999    __
$a ok $b bmc $g 947311 $s 782615
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 57 $c 2 $d 161-169 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20120816/10/02

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...